Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Aseptic Meningitis With Multiple Cranial Nerve Symptoms Induced by Atezolizumab for Lung Adenocarcinoma: A Case Report.

Created on 31 Jul 2026

Authors

Satsuki Mikoshiba-Takahashi, Taiki Matsubayashi, Michiatsu Masuda, Kasumi Tsukamoto, Takashi Yamana, Mitsuhiro Kamimura

Published in

Cureus. Volume 18. Issue 6. Pages e111696. Epub Jun 28, 2026.

Abstract

We report a case of immune-related aseptic meningitis (irAE meningitis) presenting with multiple cranial nerve symptoms during immune checkpoint inhibitor therapy for lung adenocarcinoma. A 72-year-old woman diagnosed with left lower lobe lung adenocarcinoma initiated combination therapy consisting of carboplatin, paclitaxel, bevacizumab, and atezolizumab. Paclitaxel was subsequently discontinued due to peripheral neuropathy, and maintenance therapy with bevacizumab and atezolizumab followed. Eight months after starting treatment (after four cycles of atezolizumab maintenance), the patient presented with a three-week history of dysgeusia, anosmia, trismus, and neck pain. Cerebrospinal fluid (CSF) analysis revealed lymphocytic and monocytic pleocytosis, while cytological examination showed no malignant cells and bacterial cultures were negative. Brain and neck magnetic resonance imaging (MRI) showed no alternative etiologies. Intravenous prednisolone led to a rapid resolution of all symptoms. The patient was diagnosed with irAE meningitis with concomitant cranial nerve involvement, including the olfactory (I), trigeminal (V), facial (VII), and/or glossopharyngeal (IX) nerves. Intravenous prednisolone led to a rapid resolution of all symptoms. Although irAE meningitis is a known rare adverse event, cases complicated by multiple cranial nerve symptoms are extremely uncommon. This case highlights the phenotypic diversity of neurotoxicity associated with immune checkpoint inhibitors.

PMID:
42534193
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement